A recent report has demonstrated that CD133 monoclonal Ab could increase the susceptibility of HCC cells to doxorubicin and cisplatin by inhibiting autophagy and promoting cancer cell death [100]. Here, PROM1 is linked to hepatocellular carcinoma.